Artwork
iconShare
 
Manage episode 463832448 series 3514615
Content provided by EIC Scaling Club. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EIC Scaling Club or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.

  continue reading

44 episodes